Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults

Burkitt lymphoma patients with bulky disease often have bone marrow involvement. However, leukemic presentation of Burkitt lymphoma in the absence of a mass (pure Burkitt leukemia; PBL) is uncommon. Both PBL and Burkitt lymphoma/leukemia, presenting with a tumor mass and marrow involvement (BLL), ar...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2016-04, Vol.57 (4), p.866-871
Main Authors: Song, Joo Y, Venkataraman, Girish, Fedoriw, Yuri, Herrera, Alex F, Siddiqi, Tanya, Alikhan, Mir B, Kim, Young S, Murata-Collins, Joyce, Weisenburger, Dennis D, Liu, Xueli, Duffield, Amy S
Format: Article
Language:English
Subjects:
Adult
Aged
Bone Marrow - pathology
Burkitt Lymphoma - mortality
Burkitt Lymphoma - pathology
Burkitt Lymphoma - therapy
Combined Modality Therapy
Female
Humans
Karyotype
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Retrospective Studies
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Burkitt lymphoma patients with bulky disease often have bone marrow involvement. However, leukemic presentation of Burkitt lymphoma in the absence of a mass (pure Burkitt leukemia; PBL) is uncommon. Both PBL and Burkitt lymphoma/leukemia, presenting with a tumor mass and marrow involvement (BLL), are considered stage IV disease, which is associated with a poor prognosis. However, there is limited information on the prognosis in adults with PBL because they have typically been included in cohorts of patients with BLL. This study identified 23 patients, which included 10 PBL and 13 BLL cases. Complex karyotypes (100%) were seen in all BLL cases compared to the PBL group (40%; p = 0.061). Patients with PBL had a significantly better 5-year overall survival of 87.5% vs only 24.3% in the BLL group (p = 0.005). The 5-year overall survival of patients with PBL treated with intensive chemotherapy is superior to those with BLL who are similarly treated.
ISSN:1042-8194
1029-2403
DOI:10.3109/10428194.2015.1085529